Targeting B cell receptor signalling in cancer: Preclinical and clinical advances

Keyphrases

• In Cancer 100%
• B-cell Receptor Signaling 100%
• Clinical Progress 100%
• B Cell Receptor 66%
• Cell-to-cell 33%
• B Cells 33%
• B-cell Malignancies 33%
• Solid Tumors 16%
• Pancreatic Cancer 16%
• Autoantigen 16%
• Signal Component 16%
• Squamous Cell Carcinoma (SqCC) 16%
• B-cell Lymphoma 16%
• B-cell Leukemia 16%
• Activating mutation 16%
• Microenvironment 16%
• Anticancer Activity 16%
• Pathway Activation 16%
• Normal B Cells 16%
• Downstream Signaling 16%
• Tonic 16%
• Bruton's Tyrosine Kinase 16%
• Ligand-independent 16%
• Tissue Microenvironment 16%
• Malignant B Cells 16%
• Bruton Tyrosine Kinase Inhibitor 16%
• B Cell Development 16%
• Adaptive Immunity 16%
• Complex Signal 16%
• Microbial Antigens 16%
• Isoform-selective Inhibitor 16%
• PI3K Isoforms 16%

Medicine and Dentistry

• Malignant Neoplasm 100%
• B Lymphocyte Receptor 100%
• B Cell 50%
• Cancer 20%
• Kinase 20%
• Diseases 10%
• Squamous Cell Carcinoma 10%
• Solid Malignant Neoplasm 10%
• Pancreas Cancer 10%
• B-Cell Lymphoma 10%
• Antineoplastic Activity 10%
• B Cell Leukemia 10%
• Adaptive Immunity 10%
• Bruton Tyrosine Kinase 10%
• Bruton Tyrosine Kinase Inhibitor 10%
• B Cell Development 10%
• Autoantigen 10%